Aggregated from the cited literature below. We summarize sources — we don't author claims.
Pramlintide is a synthetic analogue of the human hormone amylin and is described as an amylinomimetic compound. Review literature reports that it is used clinically as an adjunct to insulin therapy for type 1 and type 2 diabetes, and that amylin agonists (including pramlintide) have been investigated for potential weight-loss effects in obesity research, including in combination with other agents. (PMIDs: 26071095, 16278328, 34288673, 30000033, 39317404)
Mechanism (as reported)
A review describes amylin as activating specific multisubunit G protein-coupled receptors (with multiple receptor subtypes) and functioning in glucoregulatory energy metabolism and other reported organ-system effects. (PMID: 26071095) A pramlintide-focused review reports that pramlintide complements insulin’s effects in postprandial glucose regulation by decreasing glucagon secretion; it is also reported to slow gastric emptying and reduce postprandial glucose levels. (PMID: 16278328)
Key findings (each cites a source)
Pramlintide is described as a synthetic analogue of the human hormone amylin and as an amylinomimetic compound. (PMID: 16278328) [PMID 16278328]
Amylin is described as a 37-amino-acid peptide that activates specific multisubunit G protein-coupled receptors, resulting in multiple receptor subtypes. (PMID: 26071095) [PMID 26071095]
A review reports that pramlintide is used clinically to treat type 1 and type 2 diabetes. (PMIDs: 26071095, 16278328) [PMID 26071095, 16278328]
A review reports that pramlintide is used as an adjunct to insulin therapy for patients with diabetes who have failed to achieve glycemic control despite optimal insulin therapy. (PMID: 16278328) [PMID 16278328]
A pramlintide review reports that pramlintide decreases glucagon secretion and complements insulin’s effects in postprandial glucose regulation. (PMID: 16278328) [PMID 16278328]
A pramlintide review reports pramlintide slows gastric emptying and reduces postprandial glucose levels. (PMID: 16278328) [PMID 16278328]
A pramlintide review reports that pramlintide is predominantly renally eliminated and has a mean elimination half-life of about 30–50 minutes. (PMID: 16278328) [PMID 16278328]
A pramlintide review reports an increased risk of insulin-induced severe hypoglycemia, along with adverse events such as nausea, anorexia, fatigue, and vomiting. (PMID: 16278328) [PMID 16278328]
A review reports that clinical studies in obesity indicate amylin agonists (including pramlintide) could be useful for weight loss, especially in combination with other agents. (PMID: 26071095) [PMID 26071095]
A source describing amylin analogs for obesity reports that pramlintide has demonstrated weight-lowering action and that clinical trials confirmed weight loss exceeding 3% during the study period, maintained beyond follow-up, without major untoward effects (as characterized in that source). (PMID: 39317404) [PMID 39317404]
A source on longer-acting amylin analogue development reports that pramlintide is commercially available for diabetes treatment but requires three daily injections due to short half-life, motivating development of a longer-acting analogue (cagrilintide). (PMID: 34288673) [PMID 34288673]
Independent test grades
No independent third-party test data is available for Pramlintide yet. Our test grades are aggregated from Finnrick, which independently tests a subset of research peptides — many approved drugs and newer or niche compounds aren't covered.
Research literature (9)
Consolidated from PubMed — each links to the original record.
McQueen J · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2005 · PMID 16278328
FAQ
What is Pramlintide?
Pramlintide (Triproamylin, pramlintida, TRIPRO-AMYLIN) is classified under amylin analogs, an FDA-approved drug. Research goals associated with it include metabolic & weight.
Is Pramlintide FDA-approved?
Yes — Pramlintide is approved by the FDA (marketed as Triproamylin, pramlintida).
What does the research on Pramlintide say?
peptideone aggregates 9 references from PubMed for Pramlintide. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.